<DOC>
	<DOC>NCT01496040</DOC>
	<brief_summary>The purpose of the study is to assess the safety and efficacy of the active substance rAAV-2/4.hRPE65 in patients with Leber Congenital Amaurosis or Congenital severe early-onset retinal degeneration associated with RPE65 mutation.</brief_summary>
	<brief_title>Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65</brief_title>
	<detailed_description />
	<mesh_term>Leber Congenital Amaurosis</mesh_term>
	<mesh_term>Blindness</mesh_term>
	<mesh_term>Retinal Dystrophies</mesh_term>
	<criteria>Mutations that code for abnormal RPE65 protein Presence of characteristic abnormalities in fundus Dramatic reduction of both rods ans cones ERG responses Low visual acuity &lt;0.32 inform consent signed Patients with chronic conditions such a haematological, cardiac, renal diseases Patients with, within the past 6 months, a clinically significant cardiac disease or known congestive heart failure, cardiac rhytm and conduction abnormalities Patients with pulmonaty dysfunction Patients with suspected rheumatoid arthritis Patients with current systemic infection........</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>